Advancing Interventions to Improve Medication Adherence (R21)

The summary for the Advancing Interventions to Improve Medication Adherence (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Advancing Interventions to Improve Medication Adherence (R21): This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes. This FOA encourages Exploratory/Developmental Research Project Grant (R21) applications for research and development of interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Applicants should demonstrate the feasibility of collecting multi-modal data on the targets of the intervention including: a patient self-report of medication adherence, at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.), and a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under this mechanism should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.
Federal Grant Title: Advancing Interventions to Improve Medication Adherence (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-14-335
Type of Funding: Grant
CFDA Numbers: 93.173, 93.242, 93.273, 93.361, 93.393, 93.395, 93.399, 93.867
CFDA Descriptions: Research Related to Deafness and Communication Disorders; Mental Health Research Grants; Alcohol Research Programs; Nursing Research; Cancer Cause and Prevention Research; Cancer Treatment Research; Cancer Control; Vision Research
Current Application Deadline: Jan 7, 2018
Original Application Deadline: Jan 7, 2018
Posted Date: September 5th, 2014
Creation Date: Sep 5, 2014
Archive Date: Feb 7, 2018
Total Program Funding:
Maximum Federal Grant Award: $275,000
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
For profit organizations other than small businesses
County governments
State governments
Public and State controlled institutions of higher education
Special district governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PA-14-335.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
More Grants from the National Institutes of Health
Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not A...
Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (S...
Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not All...
PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com